2017
Gardner, J., Higham, R., Faulkner, A., & Webster, A. (2017). Promissory Identities: Sociotechnical Representations & Innovation in Regenerative Medicine. Social Science & Medicine 174: 70-78.

Gardner, J., & Webster, A. (2017). Tensions in the creation of biovalue: The Cell and Gene Therapy Catapult as an innovation accelerator agency. Science, Technology & Human Values. 

2016
Faulkner, A. (DATE) Opening the gateways to market and adoption of regenerative medicine? The UK case in context, Regenerative Medicine Vol. 11, (3): 321-330.

Gardner, J., & Webster, A. (2016). The Social Management of Biomedical Novelty: Facilitating translation in regenerative medicine, Social Science and Medicine, vol 156:90-97.doi:10.1016/j.socscimed.2016.03.025

Mahalatchimy, A. (2016). Accreditation and regulations in cell therapy, ISBT Science Series (2016) 11 (Suppl. 1), 271–276.

Mahalatchimy, A. (2016). The reimbursement of cell- based regenerative therapy in the UK and France, The Medical Review.

Gardner, J., & Webster, A. (2015). Are there specific translational challenges in regenerative medicine? Lessons from other fields, Regenerative Medicine, Vol. 10 (5) 885-895. doi:10.2217/rme.15.50

Posters

Autologous vs allogeneic cell based regenerative therapies (PDF , 102kb)

Profiling characteristics of the RM reimbursement publications landscape (PDF , 1,051kb)

Clinical trials and the challenge of regenerative medicine (PDF , 142kb)

RegMedPoster_Inst readiness (PDF , 533kb)